de Heus Roel, Mulder Eduard J H, Derks Jan B, Visser Gerard H A
Department of Perinatology and Gynecology, University Medical Centre Utrecht, The Netherlands.
Obstet Gynecol Surv. 2008 Jun;63(6):383-8; quiz 405. doi: 10.1097/OGX.0b013e31816ff75b.
This review critically evaluates the efficacy of different tocolytics in reducing uterine pressure and contractions in term labor. The available evidence supports the use of beta-adrenergic-receptor agonists such as terbutaline or ritodrine; they appear to have an immediate and comparable profound effect on uterine activity in term labor. However, the preferred type of beta-adrenergic receptor agonist and dosage are unclear. The oxytocin receptor antagonist atosiban has a high specificity for the uterus with limited or no systemic effects and could therefore be an attractive alternative for use in term labor. The evidence on the tocolytic potency of a single bolus of atosiban for tocolysis in term labor is encouraging but limited and needs further research. Moreover, atosiban lacks United States Food and Drug Administration approval. Literature documenting efficacy and safety of nitroglycerin or magnesium sulfate in term labor is far from convincing. The theoretical basis for the use of tocolytics for nonreassuring intrapartum fetal heart rate patterns is to reduce the aggravating influence of uterine contractions. However, the clinical evidence that tocolytics in term active labor are actually beneficial in improving neonatal outcome is very limited.
本综述批判性地评估了不同宫缩抑制剂在足月分娩时降低子宫压力和宫缩的疗效。现有证据支持使用β-肾上腺素能受体激动剂,如特布他林或利托君;它们似乎对足月分娩时的子宫活动有直接且相当显著的影响。然而,β-肾上腺素能受体激动剂的首选类型和剂量尚不清楚。缩宫素受体拮抗剂阿托西班对子宫具有高度特异性,全身作用有限或无全身作用,因此可能是足月分娩时一种有吸引力的替代药物。关于单次推注阿托西班在足月分娩中用于抑制宫缩效力的证据令人鼓舞,但有限且需要进一步研究。此外,阿托西班尚未获得美国食品药品监督管理局的批准。记录硝酸甘油或硫酸镁在足月分娩中疗效和安全性的文献远不能令人信服。使用宫缩抑制剂治疗产时胎儿心率异常的理论依据是减少子宫收缩的加重影响。然而,关于足月活跃期分娩时宫缩抑制剂实际上有利于改善新生儿结局的临床证据非常有限。